Institutional Research Archive

Hedge Fund Letters Archive

Browse the world's most comprehensive database of hedge fund investor letters, sorted by recent quarter. Access primary source research from leading institutional managers.

Quarter	Letter Date	Fund Name	QTD	YTD	Tickers	Themes	Quick Take

Home Letters Funds Account

The Wolf of Harcourt Street 2024 Q1 Investor Letter | Buyside Digest

Back to Fund Profile (The Wolf of Harcourt Street)

Primary Source Intelligence • Q1 2024 Letter Analysis

The Wolf of Harcourt Street Quarterly Analysis

Buyside Digest is not affiliated with, and does not endorse, The Wolf of Harcourt Street. This analysis is provided for institutional research purposes only and is not investment advice.

Fund Returns

Annualized+14%

Digest Analysis

Quick Take

"Outperforming benchmarks by focusing on healthcare overweight and high-growth companies. Portfolio includes prostate diagnostics leader MDxHealth, specialty pharma Xeris, and AI marketing platform Zeta Global."

Executive Summary

The fund delivered strong Q3 2025 performance with returns of +18% to +25% net across portfolios, outperforming Russell 2000 Growth (+12%) and Russell 2500 Growth (+7%). The manager remains optimistic about portfolio companies' ability to deliver positive fundamentals regardless of economic backdrop. The fund has strategically shifted toward an overweight in healthcare, viewing it as both offensive and defensive given new products addressing large market opportunities and nondiscretionary characteristics. Key contributors included MDxHealth (prostate cancer diagnostics), Xeris Pharmaceuticals (Cushing's Syndrome treatment), and Zeta Global (AI-powered marketing technology). The manager notes that small and mid-cap stocks trade at attractive 16x earnings versus elevated valuations for mega-cap stocks. While acknowledging AI infrastructure investments by large tech companies, they remain cautious about long-term capabilities versus current expectations. With the Fed cutting rates and historical small-cap outperformance during cutting cycles, the manager continues screening for companies with strong growth and margins while monitoring macroeconomic uncertainties.

Unlock Full Institutional Analysis

Sign in or create a free account to unlock full commentary, extracted equity pitches, and direct outbound manager source links with your 3 quarterly credits.

Sign In to Unlock (3 Free Credits)View Pricing Tiers

Institutional Meta Strategy

Meta Strategy Gauges

Algorithmic conviction, macroeconomic posture, and risk appetite signals extracted from this quarterly letter with qualitative explanations.

Signal Matrix

Market Conviction

72%

CautiousHigh

High Conviction (72%)

The manager demonstrates high conviction through detailed analysis of specific holdings (MDXH, XERS, ZETA) with clear thesis explanations, valuation metrics, and growth drivers. They name positions, discuss entry points, and explain why they continue holding despite volatility. The strategic healthcare overweight and specific company analysis shows strong conviction in their picks.

Growth Outlook

60%

BearishBullish

Neutral (60%)

The manager expresses optimism about portfolio companies delivering positive fundamentals and sees tremendous investment opportunities. They note attractive small-cap valuations versus elevated large-cap multiples and expect rate cuts to benefit stocks, particularly small companies historically.

Risk Appetite

40%

DefensiveAggressive

Defensive (40%)

The fund has taken some gains and tried to offset with losses for tax purposes, suggesting some profit-taking. They've shifted to healthcare overweight for defensive characteristics while maintaining growth focus, indicating moderate risk appetite with some defensive positioning.

Capital Deployment

10%

De-riskingDeploying

De-risking (10%)

The letter indicates some profit-taking with gains being harvested and offset with losses for tax purposes. No specific cash level changes are mentioned, and the activity described appears to be portfolio rotation rather than net deployment or de-risking.

Forward Guidance

50%

CautiousExpansionary

Neutral (50%)

The manager states they continue to see tremendous investment opportunities and are actively screening for new ideas. However, they're also cautiously monitoring macroeconomic events, showing balanced deployment intentions without strong directional bias.

Language Signal

45%

BearishBullish

Balanced (45%)

Language includes positive terms like 'tremendous investment opportunities,' 'optimistic,' and 'attractive valuations' but is balanced with caution about 'uncertainty in macroeconomic and political landscape' and concerns about AI capabilities versus expectations.

Perceived Risk

45%

Low RiskElevated

Moderate Risk (45%)

The manager acknowledges uncertainty in macroeconomic and political landscape and notes elevated valuations for large-cap stocks. They express caution about AI capabilities potentially being less than expected long-term, but these risks are mentioned without detailed elaboration or systemic concern.

Opportunity Density

75%

ScarceAbundant

Abundant (75%)

The manager explicitly states they 'continue to see tremendous investment opportunities in the market' and are 'continuously screening for companies with new products and services.' They highlight attractive small-cap valuations and believe the environment favors active stock selection over passive investing.

Time Horizon

65%

Short-TermLong-Term

Multi-Year (65%)

The manager demonstrates a multi-year investment horizon, holding XERS despite doubling since June due to 'large opportunity ahead' and discussing XERS's 2030 revenue model of $750 million. They focus on fundamental company performance regardless of economic backdrop, suggesting patience for thesis realization over 2-3 years.